Stock Chart

RIGL

$47.15 +0.38%
Score: 56.7 HOLD
LEAPs: SELL $48
i
LEAPs Option Signal

Type: SELL wallstreet
Strike: $48
Premium: $9.09
Expiry: Jun 18, 2026
Target: $47
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 0.80x (vs SPY: 0.8x | vs QQQ: 0.8x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Oct 02, 2026
Rising Wedge Bearish scenario quality 65/100
Measured-move target $47.15 (-0.0%) · apex ~22 bars ahead
Historically breaks down 72% of the time; target hit in 78% of down-breaks (n=653)
Pattern detection is automated and probabilistic — a scenario map for levels, not a buy/sell signal. Rails, projected path and target are drawn on the chart below.
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About RIGL - Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Key Statistics

Market Cap $877M
P/E Ratio 2.85

This RIGL stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track RIGL's price movements with trendlines, gamma walls, and key support/resistance levels.